The French clinical stage biotech treats blood cancers and graft-versus-host disease, achieving proof of concept in acute myeloid leukemia patients. They use a discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Their therapeutics are produced through a standardized cGMP manufacturing and quality control process. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.